The life science industries have tamed COVID-19. Now, they must continue to replenish pipelines with innovative treatments.
Fortunately, pharmas and biotechs are making rapid progress toward personalized medicine. Meanwhile, an enormous market for biologics is opening up in Mainland China. However, these industries have work to do in addressing underserved conditions and populations.